Corium International, a biopharmaceutical company, has raised $52 million in its IPO on the NASDAQ under the symbol CORI. Corium employs transdermal and transmucosal delivery systems to produce products like Crest Whitestrips. The final offering price was $8 per share, considerably lower than the anticipated range of $10 to $12 per share. Essex Woodlands, which held a 55.7% pre-IPO stake, remains the majority shareholder in the company. Shares closed down a notch on their debut at $7.95.